title: Attempts to improve locoregional chemotherapy for the prevention of colonic cancer liver metastasis in the rat.
abstract: OBJECTIVE
  To improve prophylactic local treatment of hepatic metastasis from colonic cancer cells in the rat.
  
  
  METHODS
  The in vitro anticancer activity of 30 mn exposure to different drugs was first evaluated by dimethyl-thiazol-diphenyl-tetrazolium-bromide assay on confluent DHD/K12/PROb rat and HT29 human colonic cancer cells. Hepatic metastasis was induced by portal vein infusion of 12 x 106 PROb colonic cancer cells in syngenic BDIX rats. Hepatic and general tolerance to epirubicin was studied. Rats were treated with epirubicin delivered by either intravenous (IV), intraperitoneal (IP) or intraportal (Ipo) administration to compare their antitumoral effects. Hepatic distribution of epirubicin was assessed by fluorescence microscopy after IV, IP, Ipo, and combined administration. High pressure liquid chromatography was used to measure hepatic concentrations of epirubicin.
  
  
  RESULTS
  Only pirarubicin was fully cytotoxic in vitro against the two types of tumor cells. No general or hepatic toxicity was observed. The preventive effect on hepatic metastasis was similar for IV, IP, and Ipo pirarubicin treatments. Hepatic pirarubicin concentrations obtained by Ipo administration were 4.1-fold higher than those obtained after IV administration (P=0.013). Three hours after IP and Ipo administration, hepatic remnants of pirarubicin were similar and significantly higher that those obtained after IV administration (P=0.074). Clamping the hepatic vein doubled hepatic pirarubicin concentrations after Ipo administration (P=0.048). Combined hepatic and intraportal administration was necessary to achieve diffuse, intense and homogeneous fluorescence throughout the entire liver.
  
  
  CONCLUSIONS
  Homogeneous hepatic diffusion of pirarubicin was successfully achieved with combined hepatic vein and intraportal administration but systemic, intraperitoneal or intraportal administration had no preventive effect on hepatic metastasis. Other drugs could be tested using this approach to evaluate their efficacy and toxicity.
authors.affiliation: Service de Chirurgie Digestive, Thoracique et Cancérologique, CHU de Dijon, Hôpital du Bocage, 1 Bd. Maréchal de Lattre de Tassigny, 21034 Dijon. laurent.benoit@chu-dijon.fr
authors.forename: Laurent
authors.initials: L
authors.lastname: Benoit
authors.forename: Patrick
authors.initials: P
authors.lastname: Favoulet
authors.forename: Pablo
authors.initials: P
authors.lastname: Ortega-Deballon
authors.forename: Nicolas
authors.initials: N
authors.lastname: Cheynel
authors.forename: Anisoara
authors.initials: A
authors.lastname: Anusca
authors.forename: Diane
authors.initials: D
authors.lastname: Bamourou
authors.forename: Franck
authors.initials: F
authors.lastname: Bonnetain
authors.forename: Patrick
authors.initials: P
authors.lastname: Rat
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Favre
authors.forename: Bruno
authors.initials: B
authors.lastname: Chauffert
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D003110:Colonic Neoplasms / Q000473:pathology*; D007262:Infusions, Intravenous; D007263:Infusions, Parenteral; D008113:Liver Neoplasms / Q000473:pathology / Q000517:prevention & control* / Q000556:secondary; D008297:Male; D011169:Portal Vein; D051381:Rats; D014407:Tumor Cells, Cultured
chemical_list: D000970:Antineoplastic Agents